20855842

Source:http://linkedlifedata.com/resource/pubmed/id/20855842

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006142, umls-concept:C0087111, umls-concept:C0205179, umls-concept:C0233820, umls-concept:C0442504, umls-concept:C0521425, umls-concept:C0935916
pubmed:issue	30
pubmed:dateCreated	2010-10-19
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20855842-20855825
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal, http://linkedlifedata.com/resource/pubmed/chemical/Estradiol, http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen, http://linkedlifedata.com/resource/pubmed/chemical/fulvestrant
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	1527-7755
pubmed:author	pubmed-author:BerghJonasJ, pubmed-author:HowellAnthonyA
pubmed:issnType	Electronic
pubmed:day	20
pubmed:volume	28
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	4548-50
pubmed:meshHeading	pubmed-meshheading:20855842-Antineoplastic Agents, Hormonal, pubmed-meshheading:20855842-Breast Neoplasms, pubmed-meshheading:20855842-Clinical Trials, Phase III as Topic, pubmed-meshheading:20855842-Disease-Free Survival, pubmed-meshheading:20855842-Drug Administration Schedule, pubmed-meshheading:20855842-Estradiol, pubmed-meshheading:20855842-Estrogen Antagonists, pubmed-meshheading:20855842-Female, pubmed-meshheading:20855842-Humans, pubmed-meshheading:20855842-Injections, Intramuscular, pubmed-meshheading:20855842-Middle Aged, pubmed-meshheading:20855842-Multicenter Studies as Topic, pubmed-meshheading:20855842-Postmenopause, pubmed-meshheading:20855842-Quality of Life, pubmed-meshheading:20855842-Randomized Controlled Trials as Topic, pubmed-meshheading:20855842-Receptors, Estrogen, pubmed-meshheading:20855842-Risk Assessment, pubmed-meshheading:20855842-Risk Factors, pubmed-meshheading:20855842-Time Factors, pubmed-meshheading:20855842-Treatment Outcome
pubmed:year	2010
pubmed:articleTitle	Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer.
pubmed:publicationType	Editorial, Comment